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Cellular and molecular synergy in AS01-adjuvanted vaccines
results in an early IFNγ response promoting vaccine
immunogenicity
Margherita Coccia1, Catherine Collignon1, Caroline Hervé1, Aurélie Chalon1, Iain Welsby2, Sophie Detienne2, Mary J. van Helden3,
Sheetij Dutta4, Christopher J. Genito4, Norman C. Waters4, Katrijn Van Deun5,6, Age K. Smilde7, Robert A. van den Berg1, David Franco1,
Patricia Bourguignon1, Sandra Morel1, Nathalie Garçon1, Bart N. Lambrecht3, Stanislas Goriely2, Robbert van der Most1 and
Arnaud M. Didierlaurent1
Combining immunostimulants in adjuvants can improve the quality of the immune response to vaccines. Here, we report a unique
mechanism of molecular and cellular synergy between a TLR4 ligand, 3-O-desacyl-4’-monophosphoryl lipid A (MPL), and a saponin,
QS-21, the constituents of the Adjuvant System AS01. AS01 is part of the malaria and herpes zoster vaccine candidates that have
demonstrated efﬁcacy in phase III studies. Hours after injection of AS01-adjuvanted vaccine, resident cells, such as NK cells and
CD8+ T cells, release IFNγ in the lymph node draining the injection site. This effect results from MPL and QS-21 synergy and is
controlled by macrophages, IL-12 and IL-18. Depletion strategies showed that this early IFNγ production was essential for the
activation of dendritic cells and the development of Th1 immunity by AS01-adjuvanted vaccine. A similar activation was observed
in the lymph node of AS01-injected macaques as well as in the blood of individuals receiving the malaria RTS,S vaccine. This
mechanism, previously described for infections, illustrates how adjuvants trigger naturally occurring pathways to improve the
efﬁcacy of vaccines.
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INTRODUCTION
Adjuvants are included in vaccines to improve humoral and
cellular immune responses, particularly with poorly immunogenic
subunit vaccines. Similar to natural infections by pathogens,
adjuvants activate the innate immune system to promote long-
lasting adaptive immunity.1 As simultaneous activation of multiple
innate pathways is a feature of infections, adjuvants such as the
Adjuvant Systems combine multiple immunostimulants to pro-
mote adaptive immune responses to vaccination.1
The Adjuvant System AS01 is a liposome-based adjuvant which
contains two immunostimulants, 3-O-desacyl-4’-monophosphoryl
lipid A (MPL) and QS-21.2 MPL is a non-toxic derivative of the
lipopolysaccharide from Salmonella minnesota. QS-21 is a saponin
fraction extracted from Quillaja saponaria Molina.2 AS01 is
included in the recently developed malaria vaccine RTS,S
(Mosquirix)3 and in other candidate vaccines in development
against herpes zoster (HZ/su),4 HIV,5 and tuberculosis.6 The
promotion of antigen-speciﬁc CD4+ T cells in addition to
antigen-speciﬁc antibodies sets AS01 apart from other adjuvants.2
AS01-adjuvanted vaccines have also been effective in challenging
populations, such as infants (with RTS,S against malaria3) and the
older adults (HZ/su against herpes zoster4).
AS01 injection results in rapid and transient activation of innate
immunity in animal models. Activated MHCIIhigh dendritic cells
(DCs), which are necessary for T-cell priming, neutrophils and
monocytes are rapidly recruited to the draining lymph node
(dLN).7 It is also recognized that the two components of AS01 can
have distinct functions. MPL signals via TLR4, stimulating NF-ĸB
transcriptional activity and cytokine production and directly
activates antigen-presenting cells (APCs) both in human and in
mice.8 QS-21 can activate the inﬂammasome in vitro9 and
promotes high antigen-speciﬁc antibody and CD8+ T-cell
responses in mice and antigen-speciﬁc antibody responses in
humans.10 However, what is less clear is how immunostimulants
function in combination.
Here, we investigate how combining immunostimulants results
in complex patterns of innate immune activation. We present
evidence from mouse, non-human primate and clinical studies
that the MPL-QS-21 combination in AS01 results in the stimulation
of de novo pathways that were not triggered by the individual
components, but were essential for the promotion of a polyfunc-
tional CD4+ T-cell response and Th1-antibody isotype switching.
We also reveal that AS01 triggers naturally occurring defense
mechanisms, including NK-cell and innate-like CD8+ T-cell
activation in the lymph node at the earliest stages of the
innate immune response. Finally, we have shown that those
mechanisms play a role in protection conferred by AS01-
containing vaccine.
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RESULTS
The combination of MPL and QS-21 induces potent adaptive
immune response to AS01-adjuvanted vaccines
We initially assessed the contribution of MPL and QS-21 in the
adjuvant effect of AS01 using the RTS,S vaccine. The RTS,S antigen
consists of a fusion of the central repeat and C-terminal ﬂanking
regions of Plasmodium falciparum circumsporozoite protein (CSP)
with the hepatitis B surface antigen (HBs), coexpressed with HBs
alone. Naive wild-type (WT) mice were immunized with RTS,S
formulated either without adjuvant, with MPL, with QS-21 (both
formulated in liposomes) or with AS01. Two immunizations were
administered 2 weeks apart and the HBs- and CSP-speciﬁc
immune response (serum IgG and T-cell responses) was measured
after the second dose. RTS,S/AS01-induced antigen-speciﬁc IgG
responses were higher than those induced by either RTS,S/MPL or
RTS,S/QS-21 (Fig. 1a). RTS,S/AS01 also induced higher antigen-
speciﬁc CD4+ and CD8+ T-cell responses than RTS,S/QS-21,
whereas RTS,S/MPL induced virtually no antigen-speciﬁc T-cells
(Fig. 1b, c). Notably, very low levels of CD8+ T-cell responses were
generated against CSP (Fig. 1c), as previously reported.11
Additionally, RTS,S/AS01 induced predominantly a Th1 response,12
with a relatively high prevalence of IFNγ+IL-2+TNFα+ phenotype
(Fig. 1b), as reported for other antigens.12, 13 As previous reports
suggested that triple-positive CD4+ T cells produce higher levels of
cytokines,14 we assessed this in WT mice immunized with HBs/
AS01 on day 0 and day 14 (Supplementary Fig. 1). HBs is the
antigen used in the Engerix vaccine and it induced cellular
responses in mice vaccinated with RTS,S/AS01(Fig. 1b, c). For each
CD4+ T-cell phenotype, the mean ﬂuorescence intensity (MFI) of
each cytokine was measured as a proxy for the level of protein
production. This analysis conﬁrmed that the triple-positive
IFNγ+IL-2+TNFα+ CD4+ T cells produced the highest levels of each
of the cytokines, in comparison with single- or double-positive
T cells (Supplementary Fig. 1). Hence, combining MPL and QS-21
in AS01 results in enhanced adaptive immune responses to RTS,S
in comparison with the individual immunostimulants.
Complex interplay between MPL and QS-21 in AS01
transcriptional response
To investigate the molecular pathways induced by AS01, we
analyzed the gene expression proﬁle in the dLN of C57BL/6 mice
injected i.m. with AS01 after 2, 4, and 6 h. Bioinformatics analysis
identiﬁed a number of genes differentially expressed over sham
treatment (differentially expressed genes = DEG; log2(fold change)
> 2; p < 0.01; Supplementary Figure 2A). Pathway enrichment
analysis of DEG showed that the response to AS01 was
concentrated at 4 and 6 h, with few pathways enriched at 2 h
(Fig. 2a). A notable exception was the pathway “Immune response
– Th17 related cytokines”, which includes multiple pleiotropic
innate cytokines (Supplementary Fig. 2B), conﬁrming that AS01
rapidly activates innate immunity in the dLN.7 The processes
enriched by AS01 included those related to cytokines, such as
interferons, MIF and IL-2. In particular, the interferon-signaling
pathway was the most highly enriched pathway at 4 and 6 h, and
contributed the most to the variability in the microarray data set
(Supplementary Fig. 2C). Moreover, at 6 h, an IL-10-driven anti-
inﬂammatory pathway was also induced by AS01.
Fig. 1 MPL and QS-21 act synergistically to induce strong antigen-speciﬁc CD4+ T-cells and antibody responses. C57BL/6 mice were
immunized twice 2 weeks apart with the RTS,S antigen formulated together with indicated adjuvants (RTS,S= 50 µg/ml, AS01=MPL + QS-21,
MPL= 50 µg/ml, QS-21= 50 µg/ml, 2 × 50 µl/injection, i.m.). a 14 days after the last immunization, antigen-speciﬁc IgG titers were assessed by
ELISA (n= 30 mice/group, 1 out of 2 independent experiments is shown). b, c Spleens were obtained 7 days after the last dose of vaccine and
splenocytes were restimulated with a pool of peptide spanning the length of HBs or CSP. b Antigen-speciﬁc cytokine production by CD4+
T cells as assessed by ICS. c Antigen-speciﬁc cytokine production by CD8+ T cells as assessed by ICS (n= 5 mice/group, 1 out of 2 independent
experiments is shown). Bar charts show mean± SEM
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To understand the contribution of MPL and QS-21 to gene
expression induced by AS01, we compared the transcription
response of the three adjuvants (pathways enriched in MPL and
QS-21-induced responses are described in Supplementary Fig. 2D).
To go beyond the simple pairwise comparison between immu-
nostimulants, we used a statistical approach initially designed for
the analysis of combination drugs.15 This approach categorizes the
potential contributive relationships that MPL and QS-21 provide in
AS01 for each gene expressed (Fig. 2b, examples are shown in
Supplementary Fig. 2D). As shown by the high proportion of
genes falling into the irrelevance of MPL or irrelevance of QS-21
categories, over half the genes affected by AS01 can be ascribed
as MPL-speciﬁc or QS-21-speciﬁc (Fig. 2c). Altogether, those MPL-
or QS-21-speciﬁc genes were generally more frequent than genes
affected in an additive fashion by MPL and QS-21. Beyond the
simple additive effect, a number of genes were affected in a
synergistic fashion and interestingly, we also identiﬁed a group of
genes which were not induced by either QS-21 or MPL
immunization alone, but which were present in AS01-immunized
animals (Fig. 2c). We classiﬁed these genes as “emergent”.
Principal component analysis (PCA) was then used to assess
which relationships contributed the most to the variation in gene
expression over time after injection of AS01 or PBS. The ﬁrst 2
principal components (PCs) accounted for 78% of the variance
(PC1 = 58%, PC2 = 20%; see bivariate plot Fig. 2d). Projecting each
sample in this plot showed good separation between PBS and
AS01 samples (across PC1), and between samples at different time
points (across PC2). Further analysis showed that PC1 was enriched
in early emergent genes, together with genes driven by QS-21 (as
shown by enrichment in the irrelevance of MPL category). PC2 data
were instead enriched with genes driven by antagonistic and
additive interplays, together with QS-21-driven interplays such as
potentiation by QS-21 and inhibitory by QS-21. Overall, this analysis
highlights the importance of emergent interplays and QS-21-
driven effects in the transcriptional response to AS01.
Innate IFNγ promotes adaptive immune response to AS01
adjuvanted antigens
Our analysis showed that interferon-related signals were enriched
in the transcriptional response to AS01 (Fig. 2a and
Fig. 2 Statistical analysis reveals multiple types of interplays between the components of AS01. C57BL/6 mice (n= 3/adjuvant/time point)
were immunized once with HBs + AS01=MPL + QS-21, MPL = 100 µg/ml, QS-21= 100 µg/ml, 2 × 50 µl injections, i.m). Draining lymph nodes
(dLNs) were isolated at indicated time points and gene expression was assessed by microarray analysis. Linear models and contrast analysis
were used to identify differentially expressed genes (DEGs, cutoffs: fold Change> 2, p-value for contrast < 0.01, adjusted for multiple
comparisons). a Functional analysis of DEGs was performed in MetaCore. The top 10 most enriched process networks for each time point are
presented. Hierarchical clustering by column was performed to highlight similarities between time points. b A taxonomy of possible interplays
between QS-21 and MPL in AS01 is shown. The conditions to be met for each category are represented in bold. Mi represents the gene
expression level for each gene i. Numbers in italics represent the number of AS01 DEGs belonging to each category at 2 h, 4 h, and 6 h after
immunization, respectively. c Plots represent the distribution of AS01 DEGs among the different interplay catagories. The size of each pie is
proportional to the total number of DEGs at that time point. d Principal componant (PC) analysis was used to reduce the dimensionality of the
DEG list. PC1 and PC2 are represented here, together with the scores of each sample.Word Clouds represent the interplay enriched in each PC’s
loadings. The size of the character is proportional to the –log(p-value) of the enrichment, while the intensity of the color is proportional to the
effect size
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Supplementary Fig. 2C). A more focused evaluation of this
signature at 4 h revealed a strong, synergistic induction of Ifng
and the induction of number of genes in its signaling pathway,
including Stat1, Jak2, and Ifngr2 (Fig. 3a). Noticeably, genes in this
pathway fell into a number of interplay categories, highlighting
how within a same function, MPL and QS-21-mediated signals
contribute in different ways to the response to AS01.
Numerous studies indicate an important role for innate
immune-derived IFNγ in the induction of protective CD4+ T-cell
responses to infections.16–19 We have previously shown that the
innate immune response to AS01, but not to AS04 or emulsion-
based adjuvants, is characterized by IFNγ-related cytokine
production in the dLN.7, 20, 21 To conﬁrm the synergistic induction
of IFNγ by MPL and QS-21 in AS01, we analyzed the levels of this
cytokine in the dLN after immunization with HBs adjuvanted with
AS01 or its components. AS01-induced the early production of
IFNγ and the IFNγ-related cytokines CXCL9 and CXCL10, with IFNγ
and CXCL10 concentrations peaking at 6 h (Fig. 3b). In
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comparison, MPL and QS-21 also induced CXCL9 and CXCL10
production, albeit at concentrations lower than those observed
with AS01. However, they failed to signiﬁcantly induce IFNγ (Fig.
3b). AS01 also induced signiﬁcantly higher level of IFNγ mRNA at
4 h than MPL or QS-21 alone (Fig. 3c).
The requirement for IFNγ in the induction of an adaptive
immune response was ﬁrst assessed in IFNγR-deﬁcient mice. Mice
received two i.m. injections on Day 0 and Day 14 of AS01-
adjuvanted or unadjuvanted vaccines containing two antigens,
HBs and ovalbumin (OVA). HBs was selected because it is clinically
relevant, and OVA was selected because it allows Ag-speciﬁc CD8+
T cells to be detected using SIINFEKL-H2Kb pentamers. On Day 21,
splenocytes were restimulated with HBs peptides and analyzed by
intracellular cytokine staining (ICS) (Fig. 3d). As expected, the
AS01-adjuvanted vaccine (HBs + OVA/AS01) elicited much stron-
ger HBs-speciﬁc CD4+ and CD8+ T-cell responses than the non-
adjuvanted vaccine (Fig. 3e–g). Immunization with HBs + OVA/
AS01 induced very limited Th2 and Th17 responses, which were
unaffected by IFNγR deﬁciency (Supplementary Fig. 3). In IFNγR-
deﬁcient mice, HBs + OVA/AS01 elicited a much lower HBs-speciﬁc
CD4+ T-cell response than in WT mice, with CD4+ T cells producing
more than one cytokine particularly affected (Fig. 3e, f). HBs +
OVA/AS01 also elicited a lower (although not signiﬁcant) OVA-
speciﬁc CD8+ T-cell response than WT mice (interaction p-value =
0.16; Fig. 3g). The overall IgG titers to HBs + OVA/AS01 were
unaffected by the IFNγR deﬁciency, but IFNγR−/− mice showed
decreased titers of Ag-speciﬁc IgG2c antibodies (Fig. 3h).
As the IFNγR deﬁciency may affect the response to vaccination
beyond the activity of AS01 on the innate phase of the response,
we depleted early IFNγ in the dLN by administrating a low dose of
αIFNγ antibody (XMG1.2, 100 μg i.p.22) or an isotype antibody
control to WT mice 2 days before vaccination with HBs + OVA/
AS01. As shown in Fig. 3i, j, a single administration of αIFNγ mAb
resulted in lower HBs-speciﬁc CD4+ T-cell responses in IFNγ-
depleted mice than in control mice. By contrast and similar to
what was observed in the IFNγR-deﬁcient mice, the αIFNγmAb did
not signiﬁcantly lower OVA-speciﬁc CD8+ T-cell responses or
humoral responses (Fig. 3k, l). Overall, these data indicate that
IFNγ production in the early phase after vaccination is important
for the induction of polyfunctional CD4+ T-cell response (mainly of
a Th1 phenotype) and impact the quality of the antibody response
to AS01-adjuvanted antigens.
Given that IFNγ is known to modulate the function of APCs, we
addressed its role in promoting the accumulation and maturation
of innate immune cells in the dLN after injection of AS01. We have
previously shown that AS01 induces the recruitment of neutro-
phils, monocytes, and DCs in the dLN, peaking at 24 h after
injection.7 As expected, in the dLN of WT mice, HBs/AS01 elicited
the recruitment of CD11b+ Ly6GHi neutrophils, CD11b+ Ly6CHi
monocytes and CD11c+MHCIIHi DCs compared with non-
adjuvanted HBs (Fig. 4a). In IFNγR-deﬁcient mice, HBs/AS01
elicited a similar recruitment of neutrophils and monocytes to
that in WT mice, but elicited a lower (although not signiﬁcant)
recruitment of DCs (Fig. 4a). Additionally, these recruited DCs
expressed lower levels of the costimulatory molecules CD40,
CD86, and CD80 (Fig. 4b, c) than those DCs in WT mice. Overall,
these data show that the early IFNγ signal in response to AS01 is
important in promoting APC activation, which may explain the
impact on T-cell and antibody responses described above.
NK cells and CD8+ T cells produce IFNγ in the dLN within the ﬁrst
6 h of the response to AS01
The source of early IFNγ production in the dLN after injection of
AS01 was investigated by ﬂow cytometry. This showed that CD45+
cells produce IFNγ after 6 h (Fig. 4d). The CD45+ IFNγ+ population
was composed on average of ≈51% NK cells, ≈37% TCR
αβT cells (mainly CD8+ T cells), ≈1.5% NKT cells and ≈10% of
other cells (Fig. 4e). Overall, ≈33% of NK cells produced IFNγ,
whereas only 0.2% of CD8+ T cells produced IFNγ. When
compared with AS01, MPL or QS-21 induced only a minimal
accumulation of IFNγ+ cells in the dLN at 6 h (Fig. 4f), conﬁrming
the synergistic induction of IFNγ by AS01. Moreover, the relative
proportion of cells producing IFNγ differed in mice injected with
AS01, MPL, or QS-21 (Fig. 4g). Notably, in mice injected with MPL,
NK cells contributed to IFNγ production (≈41% IFNγ+CD45+ cells),
whereas, in QS-21-injected mice, NK cells contributed little to
IFNγ+ cells (≈6% IFNγ+CD45+ cells). The proportion of IFNγ+ CD8+
T cells differed between conditions (≈32% of IFNγ+CD45+ cells
with AS01, ≈16% with MPL and ≈20% with QS-21); and the
proportions of IFNγ+ NKT cells and IFNγ+ TCRγδ+ cells were
generally low (NKT + TCRγδ+cells combined: ≈5% of IFNγ+CD45+
cells with AS01; ≈2% with MPL and ≈3% with QS-21). These data
conﬁrm that QS-21 and MPL in AS01 synergistically induce early
IFNγ production by NK cells and CD8+ T cells in the dLN.
We found that AS01-induced IFNγ+NK cells were CD49b+(DX5+),
Eomes+, RORγ-, a phenotype compatible with conventional
NK cells (Fig. 5a). Murine NK-cells developmental stages can be
classiﬁed via the differential expression of the markers CD27 and
CD11b.23 AS01-induced IFNγ+NK cells expressed high levels of
CD27, and included both CD11b+ and CD11b− populations,
phenotypes consistent with a high cytokine-producing capacity
(Fig. 5a).23 In addition, the high-expression levels of CD44, CD69,
and CD25 in IFNγ+NK cells in comparison with IFNγ- NK cells
suggest that they are activated effector cells (Fig. 5a). By contrast,
IFNγ+ NK cells expressed lower levels of the chemokine receptor
CXCR3 than their IFNγ- counterparts (Fig. 5a). IFNγ+ CD8+ T cells
were CD49blow, Eomes+, CD122+, CXCR3+, and for the majority
CD44HiCD49dlow (Fig. 5b, c). Together with their rapid IFNγ
response to AS01, this phenotype suggests that most CD8+
T cells are unconventional virtual memory T cells. As with IFNγ+ NK
Fig. 3 IFNγ is required for the induction of adaptive immune responses after immunization with an AS01-adjuvanted vaccine. a
Transcriptional analysis was performed as in Fig. 2. DEGs at 4 h post immunization in the “Inﬂammation interferon_signalling” process network
(MetaCore) are represented in a heatmaps showing their −log2FC over PBS and their interplay classiﬁcation. b, c C57BL/6 mice were
immunized once with HBs + indicated adjuvants (AS01 =MPL + QS-21 MPL = 100 µg/ml, QS-21= 100 µg/ml, 2 × 10 µl injections, i.m.). dLNs
were isolated at indicated time points and homogenized. b Cytokine concentration as assessed by Luminex (n= 5 mice/group, 1 out of 2
independent experiments is shown). c Levels of IFNγ mRNA transcript in the dLN as measured by RT-PCR (n= 5 mice/group). d Timeline of
immunization protocol. Mice were immunized with AS01 and HBs/OVA (HBs= 80 µg/ml; OVA= 20 µg/ml; AS01= 100 µg/ml MPL + 100 µg/ml
QS-21, 2 × 50 µl/injection i.m.) twice at a 2 week interval. At day 21 levels of antigen-speciﬁc antibodies were titrated in the serum. Spleens
were collected and splenocytes were restimulated with a pool of peptide spanning the length of HBs or OVA and analyzed by ICS. e–g C57BL/
6 or Ifngr−/− were immunized as in c. N= 6/condition, one out of two independent experiment is shown. e Frequency of total cytokine-
producing antigen-speciﬁc CD4+ T cell. f Frequency of antigen-speciﬁc CD4+ cytokine-producing species. g Frequency of OVA-speciﬁc
SIINFEKL-H2Kb+ CD8+ T cells. h Levels of HBs-speciﬁc IgG and ratio of HBs-speciﬁc IgG1/IgG2c in the serum. i–k WTmice were treated with an
αIFNγ mAb (XMG1.2, 100 µg/mouse i.p.) and 48 h later immunized with AS01 and HBs/OVA as in d. i Frequency of total cytokine-producing
antigen-speciﬁc CD4+ T cells. j Frequency of antigen-speciﬁc CD4+ T cells by cytokine expression. k Frequency of OVA-speciﬁc SIINFEKL-H2Kb+
CD8+ T cells. l HBs-speciﬁc IgG measured by ELISA in the serum. (N= 5/condition, one representative out of two independent experiments is
shown. All graphs show mean± SEM
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Fig. 4 IFNγ is required for the recruitment and activation of APCs in the dLN after immunization with an AS01-adjuvanted vaccine. WT or
Ifngr−/− mice were immunized with AS01 + HBs (HBs = 100 µg/ml, 2 × 50 µl/injection i.m.). Twenty-four hours after immunization, dLNs were
collected and innate immune populations were evaluated by FACS. a Numbers of neutrophils (CD45+CD11b+Ly6GHi), monocytes
(CD45+CD11b+Ly6CHi) and DCs (CD45+CD11c+MHCIIHi) (N= 4 for PBS injected and 5 for AS01 injected, 1 representative out of 2 independent
experiments is shown). b, c Mean Fluorescence Intensity (MFI) for indicated maturation markers on DCs. b Representative FACS histograms. c
Quantiﬁcation. (N= 5, 1 representative plot is shown). d–g C57BL/6 mice were immunized with AS01 + HBs as above. Six hours later, dLNs
were collected and the frequency and identity of IFNγ producing cells was assessed by ICS. d Representative FACS plots of all live cells
showing IFNγ+ CD45+ cells and their identity. One representative out of four independent experiments is shown. e Distribution of IFNγ+ cells
among different cell population. f C57BL/6 mice were immunized with AS01 or its components (AS01=MPL + QS-21 MPL = 100 μg/ml, QS-21
= 100 μg/ml, 2 × 10 μl injections, i.m.). After 6 h, dLNs were collected and IFNγ+ production assessed by ICS. g Pie charts showing the
distribution of IFNγ+ cells among different cell types depending on immunostimulant used. The area of the chart is proportional to the
number of IFNγ+ cells for each condition (1 out of 2 independent experiments is shown). Bar graphs show mean ± SEM. Data were analyzed by
one-way or two-way ANOVA followed by Bonferroni post hoc test to compare all groups or by unpaired Student's t-test, as appropriate
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cells, IFNγ+ CD8+ T cells also expressed the activation markers
CD25 and CD69 (Fig. 5b).
In the dLN and after the injection of AS01, the changes in
the IFNγ+ subpopulation of NK cells differed from that of the entire
NK cell population. The size of IFNγ+ NK-cell subpopulation was
largest at 6 h, returning to baseline at 24 h, while the number of
total NK cells remained the same within the same timeframe
(Supplementary Fig. 4A). Both populations then steadily increased
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by 48 h. By contrast, the size of IFNγ+ CD8+ T-cell subpopulation
steadily increased from 3 h and paralleled that of the entire CD8+
T-cell population (Fig. 5d). Finally, the induction of IFNγ+ cells was
unaffected across a range of AS01 doses (dilutions up to 25-fold of
AS01, Supplementary Fig. 4B), excluding the possibility that the
synergistic aspect of the induction of IFNγ by AS01 was dose
dependent.
As NK cells were the major IFNγ-producing cells in the dLN, we
assessed the effect of NK-cell deﬁciency on the response to AS01-
adjuvanted vaccines. For this purpose, we used a cre-lox mouse
model, in which the lethal diptheria toxin subunit was expressed
under the control of the NK-cell-speciﬁc Nkp46 promotor (NKp46-
DTA mice).24, 25 As expected, NKp46-DTA mice lacked NK cells in
the dLN (Supplementary Fig. 4C). After immunization with HBs/
AS01, serum IFNγ levels were lower in the NK-cell-deﬁcient mice
than in WT mice (Fig. 5e). In the dLN, although IFNγ production by
NK cells was abrogated, the levels of IFNγ+ CD45+ cells were
similar in the NK-cell-deﬁcient mice to that in WT mice, mainly due
to compensatory production by other cells, including T cells (Fig.
5f, g). After immunization with HBs + OVA/AS01 (as in Fig. 3d), NK-
cell deﬁciency resulted in a mild but signiﬁcant reduction in
antigen-speciﬁc CD4+ T-cell responses in the NKp46-DTA mice in
comparison with littermate controls (Fig. 5h, i), suggesting a partial
role for NK cells in promoting CD4+ T-cell response to vaccination.
Antigen-speciﬁc CD8+ T cells and antibody responses were not
affected in this model (data not shown).
Early IFNγ induction by AS01 is mediated by subcapsular
macrophages via IL-18 secretion, and supported by IL-12
Subcapsular sinus macrophages (SSM) promote innate IFNγ
responses to infections, orchestrating both NK and CD8+ T cells
in this response.26, 27 To investigate whether SSM support early
IFNγ production by AS01, we depleted SSM by i.m. administration
of clodronate liposomes 6 days before the injection of AS01.
Clodronate liposomes have been reported to efﬁciently deplete LN
macrophages, without affecting other immune-cell populations at
steady state.28 The levels of NK cells and CD8+ T cells in the dLN
were lower with clodronate treatment than with the control
treatment in mice injected with PBS or AS01, but the difference
was only signiﬁcant (in a post hoc test) in the mice injected with
AS01 (Fig. 6a). The depletion of SSM almost entirely blocked the
AS01-induced IFNγ production by lymphoid (CD45+) cells (Fig. 6b).
Given that SSM are an essential reservoir of IL-18 and that this
cytokine was required for innate IFNγ responses in the dLN upon
infection with lymph-borne bacteria,27 we investigated its role in
our model. Both NK and CD8+ T cells in the dLN expressed the
receptor for IL-18 (IL-18R), with higher levels observed on NK cells,
and no upregulation observed after AS01 injection (Fig. 6c, top).
NK cells expressed similar levels of IL-18R irrespective of IFNγ
production, whereas IFNγ+ CD8+ T cells expressed higher levels of
IL-18R than their IFNγ− counterparts (Fig. 6c, bottom). We then
investigated whether AS01-induced innate IFNγ production was
affected by IL-18 deﬁciency by using Il18−/− mice, and by
antibody-mediated depletion of IL-12 (αIL-12p40 antibody i.p. 1
day before vaccination), because of the known synergy between
IL-12 and IL-18 to promote IFNγ responses. We observed that
AS01-induced accumulation of IFNγ+ lymphoid cells was depen-
dent on both IL-18 and IL-12 (Fig. 6d). IFNγ+ NK-cell levels were
reduced in the absence of IL-18 or depletion of IL-12, and further
reduced when both cytokines were targeted (Fig. 6e). By contrast,
AS01-induced accumulation of IFNγ+ CD8+ T cells was mostly
dependent on IL-18 (Fig. 6f).
Next, we asked whether targeting IL-12 and IL-18 decreased
adaptive immune responses to vaccination. Mice were immunized
with HBs + OVA/AS01 or unadjuvanted HBs + OVA as in Fig. 3d.
Neither IL-12 depletion nor IL-18 deﬁciency signiﬁcantly affected
the HBs-speciﬁc CD4+ T-cell response to HBs + OVA/AS01 (Fig. 6g).
By contrast, IL-12 depletion together with IL-18 deﬁciency
signiﬁcantly lowered the HBs-speciﬁc CD4+ T-cell response, most
notably among the (multifunctional) HBs-speciﬁc CD4+ T cells
expressing IFNγ and at least one other cytokine (Supplementary
Fig. 5A). Overall, these results suggest that IL-18 and IL-12
contribute to the innate IFNγ response, both individually and in a
synergistic fashion. Moreover, they support the hypothesis that
these two cytokines synergize in promoting cellular adaptive
immune responses to vaccination with AS01-adjuvanted antigens.
Immunization with an AS01-adjuvanted vaccine is associated with
innate IFNγ response across species, and it is associated with
protection in a mouse model of malaria vaccination
To evaluate the relevance of our ﬁndings in mice with respect to
human vaccination, we analyzed the serum IFNγ data from a
clinical trial of the candidate malaria vaccine RTS,S/AS01 (Trial
NCT0007504912). Data were collected at 24 h after the ﬁrst RTS,S/
AS01 dose, a time point in which elevated serum IFNγ was
detectable after vaccination in mice (Supplementary Fig. 5B). RTS,
S/AS01 vaccination resulted in increased serum levels of IFNγ (Fig.
6h), indicating that an AS01-adjuvanted vaccine elicits an innate
IFNγ response in humans. To extend these ﬁndings to the dLN, we
evaluated vaccine responses in non-human primates, a more
clinically relevant species than mice. In these experiments,
macaques were vaccinated with AS01-adjuvanted VZV glycopro-
tein E (VZV) (Fig. 6i, j) or HIV recombinant fusion protein F4 (Fig.
6k). At 24 h, serum levels of IFNγ increased in the majority of AS01-
adjuvanted vaccine recipients (Fig. 6i). In the dLN at 24 h, IFNγ
levels were signiﬁcantly higher in recipients of gE/AS01 than
recipients of gE alone (Fig. 6j). After 24 h, the levels of IFNγ rapidly
subsided in both the sera and dLNs. In addition, at 24 h, the level
of CD45+ IFNγ+ cells was higher in the dLN than non-draining
lymph nodes of recipients of gE/AS01, but not in the recipients of
gE/alum (Fig. 6k). Overall, these data show that injection of AS01
results in the induction of IFNγ production locally in the dLN in a
clinically relevant model. Hence our results suggest that elevated
serum concentrations of IFNγ (that can readily be measured in
vaccinees) reﬂect the AS01-related induction of IFNγ+ lymphoid
cells in the dLN.
Finally, we depleted NK and IFNγ+CD8+ T cells in the dLN (that
express asialoGM1 [AGM1]; Supplementary Fig. 5C) by adminis-
tering α-AGM1 antibody before vaccination. At 6 h after vaccina-
tion with RTS,S/AS01, α-AGM1 treatment resulted in the transient
Fig. 5 Characterization of IFNγ+ cells in the dLN. a–c C57BL/6 mice were immunized with AS01 + HBs (HBs = 100 μg/ml, 2 × 50 μl/injection i.
m.). Six hours later, dLN were collected and the characteristics of IFNγ-producing cells were assessed by FACS. a Phenotype of IFNγ+ NK cells.
b, c Phenotype of IFNγ+ CD8+ T cells. d C57BL/6 mice were treated as in a and the accumulation of IFNγ+ NK and IFNγ+ CD8+ T cells in the dLN
at indicated time points was assessed (n= 4–8 from 1 of 2 independent experiments). Level of signiﬁcance is indicated by * for NK cells and #
for CD8+ T cells. e–g NKp46(iCre)-ROSA-stopﬂox-DTA (NKp46-DTA) or WT mice were immunized with AS01 + HBs/OVA (HBs 80 μg/ml, OVA 20 μg/
ml, 2 × 25 μl/injection i.m.) and euthanized 6 h after immunization. e IFNγ levels in the serum. f-g dLN cell suspension was restimulated ex vivo
and analyzed by ICS. f Number of IFNγ-producing cells in the dLN. g Contribution of different cell types to IFNγ+ cells. (N= 5/group). h–i
NKp46-DTA or WT mice were immunized as in Fig. 3d. h Frequency of total cytokine-producing antigen-speciﬁc CD4+ T cells. i Frequency of
antigen-speciﬁc CD4+ T cells by cytokine expression (N= 9/group). Bar charts show mean± SEM. Data were analyzed by one-way or two-way
ANOVA followed by Bonferroni post hoc test to compare all groups or by unpaired Student's t-test, as appropriate
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depletion of NK cells and IFNγ-producing CD8+ T cells in the dLN,
and in decreased IFNγ levels in the serum and dLN (Supplemen-
tary Fig. 5D–G and Supplementary Fig. 5I). To evaluate the
relevance of our ﬁndings to vaccine-induced protection, we used
α-AGM1 treatment in a mouse model of malaria vaccination and
challenge. C57BL/6 mice were immunized with RTS,S/AS01 (as in
Fig. 3d) and then challenged with transgenic Plasmodium berghei
parasites expressing the full length Plasmodium falciparum CSP.29
As almost no CSP-speciﬁc CD8+ T-cell response is elicited by RTS,S/
AS01 (Fig. 1c), this model allowed us to minimize the impact of the
reported off-target effects of α-AGM1 on adaptive CD8+ T cells.30
Treatment with α-AGM1 before vaccination with RTS,S/AS01
resulted in a decreased frequency of CSP-speciﬁc cytokine-
producing CD4+ T cells, including polyfunctional CD4+ T cells
(Fig. 6l, Supplementary Fig. 4J). By contrast, α-AGM1 treatment
3 days after vaccination did not affect CSP-speciﬁc CD4+ T-cell
frequencies (Supplementary Fig. 4H). Treatment with α-AGM1
before vaccination also lowered the titres of full-length CSP-speciﬁc
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IgGs, but levels of IgGs speciﬁc for a protective repeat epitope
were not signiﬁcantly affected (Fig. 6m).
In response to malaria challenge, all control mice (mice that did
not receive RTS,S/AS01) developed blood-stage malaria by 4 days
after challenge. By contrast, of the mice that received RTS,S/AS01
and were not treated with α-AGM1, 30% remained protected from
malaria at 12 days after challenge (consistent with human data13).
In the mice that received RTS,S/AS01 and were α-AGM1-treated,
10% remained protected to day 12 post infection (Fig. 6n). In
comparison with control mice, the risk of infection was reduced by
RTS/AS01 vaccination alone (hazard ratio = 0.224, 95% CI =
0.077–0.654), but not by RTS/AS01 vaccination and α-AGM1-
treatment (hazard ratio = 0.499, 95% CI = 0.194–1.284). Overall,
these data support the hypothesis that IFNγ-producing lymphoid
cells play an important role in promoting protective immunity
after vaccination with RTS,S/AS01.
DISCUSSION
Combination adjuvants promote potent antigen-speciﬁc immunity
and increased protection from disease upon vaccination in
humans.1 The potency of these adjuvants is likely to rely on
complex molecular and cellular interplays, which are still poorly
understood in vivo. Here, we apply a customized statistical
framework to unravel the way that MPL and QS-21 contribute to
the transcriptional response to AS01 in the dLN. We also show that
MPL and QS-21 contribute to the synergistic production of innate
IFNγ at the earliest stages of vaccination. This IFNγ production is
critical for promoting polyfunctional Th1-biased antigen-speciﬁc
CD4+ T-cell responses to AS01-adjuvanted antigens and also
impacts on the quality of the antibody response with a reduction
in Th1-isotype switching. IFNγ is mainly produced by activated NK
and CD8+ T cells, and the process is controlled by the SSMs and IL-
12/IL-18, similar to the response to pathogens.27, 31 We also
conﬁrmed the clinical relevance of these ﬁndings by showing that
IFNγ production can be detected in the serum of vaccine
recipients at 24 h after vaccination with RTS,S/AS01, and in the
dLN of NHPs at 24 h after vaccination with AS01-adjuvanted
antigens. Finally, we show that innate IFNγ production is
important in mediating protection in a mouse model of
vaccination against malaria. Altogether, the study provides new
insights into how the unique design of AS01 (that is, the speciﬁc
combination of QS-21 and MPL in AS01) can account for the
efﬁcacy of AS01-containing vaccines.
The rationale behind Adjuvant Systems and combination
adjuvants is that combining two immunostimulants may trigger
multiple immune pathways and improve the protective response
to vaccination.1, 15 Yet, so far, most analyzes of combination
adjuvants relied on visual comparisons between components in
the absence of comprehensive statistical testing.20 Here, we used
a customized taxonomy and statistical framework to understand
how MPL and QS-21 interact in AS01 at the transcriptional level. In
using this approach, we observed complex interplays, in addition
to the expected additive or speciﬁc effects related to each
immunostimulant. Noticeably, 13–15% of differentially expressed
genes were regulated in an antagonistic fashion, suggesting
interference between MPL and QS-21 downstream processes
in vivo. Moreover, 1–3% of the transcriptional response was
classiﬁed as emergent. This highlights the complexity of the
response to adjuvant systems, with new, not pre-existing proper-
ties emerging from the combination of different immunostimu-
lants. Emergent genes contributed the most to the variation in
gene expression induced by AS01, suggesting an important role of
these genes in mediating AS01’s adjuvanticity.
It is well established that IFNγ plays a crucial role in the innate
immune response to infection, and that innate IFNγ can promote a
Th1- polarizing environment in vivo.16, 32, 33 However, the role of
innate IFNγ in clinically relevant adjuvant responses has not been
investigated. We report that the combinatorial nature of AS01
promotes the production of IFNγ by lymphoid cells in the dLN in
the ﬁrst few hours after vaccination. NK cells and CD8+ T cells were
the main sources of innate IFNγ. IFNγ+ NK cells were mainly
resident in the dLN, as little recruitment of NK cells was observed
in the ﬁrst hours after vaccination. CD8+ T cells had features of
virtual memory CD8+ T cells, which have been shown to
participate in innate immune responses in an antigen-
independent fashion.34 Both the NK and the CD8+ T-cell responses
were dependent on SSMs, in a mechanism involving IL-18 and IL-
12, and independent from monocyte recruitment in the dLN, as
the responses were preserved in Ccr2−/− mice (Kaat Fierens and
Bart Lambrecht, personal communication). The innate IFNγ
response to AS01 was remarkably similar to that described
Fig. 6 Innate IFNγ production is mediated by SSM-derived IL-18, in combination with IL-12. a, b C57BL/6 were treated with 20 μl of clodronate
liposomes or control liposomes i.m. Six days later, mice were immunized with AS01 + HBs (HBs 100 μg/ml, 2 × 10 μl/injection i.m.). Six hours
after immunization, dLNs were collected and analyzed by FACS. a Effect of subcapsular sinus macrophages depletion on NK (left) and CD8+
T cells (right). b Number of IFNγ+ CD45+ cells. cWTmice were immunized with AS01 + PBS or HBs (HBs 100 μg/ml, 2 × 50 μl/injection i.m.). dLNs
were collected 6 h after immunization and IL-18R expression was assessed by FACS. Top panels show the expression of IL-18R on CD8+ T cells
or NK cells after immunization. The bottom panel shows IL-18R expression on IFNγ- or IFNγ+ populations. d–f C57BL/6 WT or Il18−/− mice were
treated with αIL-12p40 (C17.8, 0.5 mg, i.p.) and immunized the next day with AS01 + HBs. dLNs were collected 6 h after immunization. The
accumulation and frequency of IFNγ-producing cells was evaluated by ICS. d Frequency of CD45+ IFNγ+ cells. e Frequency of IFNγ+ NK cells. f
Frequency of IFNγ+CD8+ T cells. (N= 4–20, data from 2 pooled independent experiments are shown). g C57BL/6 WT or Il18−/− mice were
treated with αIL-12p40 (C17.8, 0.5 mg, i.p.) and immunized the next day with AS01 + HBs/OVA (HBs 80 μg/ml, OVA 20 μg/ml, 2 × 50 μl/injection
i.m.). Mice were immunized twice at 14 days intervals. On Day 21, spleens were collected and frequency of total cytokine-producing antigen-
speciﬁc CD4+ T cells were anlysed by ICS (n= 8, 2 pooled experiments are shown). h Healthy individuals were immunized with RTS,S/AS01 (per
0.5 ml dose: 50 μg of RTS,S, AS01= 50 μg of MPL and 50 μg of QS-21, i.m.). The concentration of IFNγ in the serum was evaluated by ELISA.
Data show fold increase in the levels of IFNγ in the serum before immunization (pre) or 24 h after injection (N= 33). i–k Chinese rhesus
macaques were immunized i.m. with AS01 (2 × 250 μl) + VZV glycoprotein E (25 μg) (i, j) or HIV recombinant protein F4 (10 μg) (k). Cytokine
levels were analyzed by multiplex bead assay and ICS. i Levels of IFNγ in the serum at indicated time points. j Levels of IFNγ in the dLN at
indicated time points. k Frequency of IFNγ-producing cells in draining and non-draining lymph node 24 h after immunization. For sera N= 7,
for dLN N= 2–4, for ICS N= 3–6. l–n Mice were immunized with RTS,S/AS01 as in Figure 3D (1 × 50 μl, i.m.). Two days before immunization and
on the day of immunization, mice were administered 100 μl of α-AGM1 Ab or control rabbit polyclonal serum. l On Day 21, spleens were
collected and splenocytes were restimulated with a pool of peptide spanning the length of CSP and frequency of total cytokine-producing
antigen-speciﬁc CD4+ T cells were analyzed by ICS. m IgG titers against full length or the NANP repeated reagions of CSP. n. Two weeks after
the last immunization, mice were infected with 3000 transgenic Plasmodium berghei sporozoites expressing Plasmodium falciparum CSP. Mice
were monitored daily and considered infected after showing parasitemia by blood smear for 2 consecutive days. Kaplan–Meyer survival
curves are shown (N= 10/group). All graphs show mean ± SEM. Data were analyzed by one-way or two-way ANOVA followed by Bonferroni
post hoc test, by Student's t-test or by paired Student's t-test, as appropriate. *p<0.05, **p< 0.01, ***p< 0.001. All charts show mean± SEM
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following infection of mice with both extracellular and intracellular
pathogens.27 These results suggest that in its induction of potent
adaptive responses to the vaccine antigen, AS01 targets the
complex prepositioning of cells in the dLN that are poised to limit
bacterial spread during an infection. Given the complexity of
AS01-mediated modulation of DC function and the heteroge-
neous population of cells in the dLN,7 further experiments are
needed to detail the interaction between NK cells and myeloid
cells in dLN. Interestingly, a recent report showed early IFNγ
production in the dLN of mice immunized with glucopyranosyl
lipid adjuvant-stable emulsion (GLA-SE).35 Although the levels
observed in that study were lower than those we report for AS01,
it should be noted that GLA-SE is also able to induce T-cell
responses in vivo,35 supporting the hypothesis that early IFNγ
production is important for obtaining productive T-cell responses
to adjuvanted vaccines.
The adjuvanticity of AS01 is at least partially mediated by the
recruitment and activation of CD11c+ MHCIIHi DCs.7 Here, we show
that the maturation of DCs is dependent on innate IFNγ release
(presumably via a cell-intrinsic mechanism36), and that IFNyR
deﬁciency or simultaneous impairment of both IL-12 and IL-18
results in defective CD4+ cellular immune responses to vaccina-
tion. In addition, mice speciﬁcally deﬁcient in NK cells developed
reduced CD4+ T-cell responses to vaccination. Overall, this
indicates that innate IFNγ is required to induce CD4+ T-cell
responses, with a Th1-bias after immunization with an AS01-
adjuvanted vaccine, as further supported by the reduction in
IgG2c antigen-speciﬁc antibodies in the absence of innate IFNγ
signals. However, the CD8+ T-cell response and the overall
magnitude of the humoral immune response were mostly
preserved in all these models suggesting that other yet
undiscovered mechanisms also contribute to AS01 adjuvanticity.
Nevertheless, the depletion of IFNγ-producing cells resulted in
decreased RTS,S-mediated protection in a malaria challenge
model, accompanied by a decreased CSP-speciﬁc CD4+ T-cell
response and limited effects on protective antibodies. This
suggests that the modulation of adaptive immunity mediated
by innate IFNγ is relevant to protection. In addition, it suggests
some role for both cellular and humoral adaptive immunity in RTS,
S-mediated protection from malaria, as hinted by ﬁndings from
clinical trials.12
As QS-21 induces inﬂammasome activation in vitro and in vivo37
and MPL induces IL-12 secretion in vitro,8 we hypothesized that
the combination of these two immunostimulants in AS01 is
essential for early IFNγ production. Accordingly, the innate IFNγ
response to AS01 was fully dependent on both IL-18 and IL-12
production in the dLN. Other members of the inﬂammasome-
dependent cytokines, such as IL-1β, might contribute to the IFNγ
response in vivo, but are likely to be redundant with IL-18.
Furthermore, the components of AS01 reach the dLN as early as
30min after immunization7 (and data not shown). The liposome
formulation of AS01 is most likely to play a role in its rapid
drainage to the dLN and activation of SSM, as liposomes can
improve the targeting of their components to the lymph node38
and promote uptake by macrophages.39
We identiﬁed innate IFNγ as a major player in the innate
immune response to AS01 in the earliest stages after immuniza-
tion. Although the role for adaptive, T-cell-derived IFNγ in
promoting effective immunization is well established,40 little
information is available regarding the role of this cytokine in the
early response to vaccination. Yet, evidence from clinical studies
suggests that major cellular and molecular changes occur in the
ﬁrst 24 hours after immunization in humans.41–43 We show that
vaccination with AS01-adjuvanted antigens results in upregulation
of IFNγ levels in the serum of human subjects and in the serum
and dLN of NHPs. Although caution should be used when
extending the ﬁndings from animal models to humans, this latter
observation supports the hypothesis that innate cells underlie
IFNγ production in humans who receive an AS01-adjuvanted
vaccine. Indeed, CD56HiCD16– NK cells are enriched in human
lymph nodes and are more efﬁcient at producing IFNγ than
peripheral-blood NK cells,44, 45 and CD8+ T cells with innate
features were recently described in human blood and cord blood
samples.46 More investigations in appropriate models such as
NHPs will be needed to understand the contribution of these cell
types to innate immune response to vaccination. Interestingly,
individuals vaccinated with RTS,S/AS01 and protected from
malaria presented increased activation of an IFN-related blood
transcriptional module at D1 post vaccination, compared with
non-protected individuals.47 However, further work will need to
fully demonstrate the requirement of an innate IFNγ response for
the induction of effective vaccination in humans. It is also possible
that such a mechanism will be ampliﬁed with successive vaccine
doses, because antigen-speciﬁc memory-T cells can promote IFNγ
production by innate immune cells.36 Indeed, a positive feedback
loop between NK cells and CD4+ T cells takes place during
vaccination, malaria and VZV infections.48–50
Overall, our study provides compelling information regarding
the mechanism of action of AS01, an adjuvant which has proven
successful in improving immunogenicity and efﬁcacy in vaccines
for challenging diseases such as malaria and herpes zoster.
MATERIALS AND METHODS
Vaccine formulations
All antigens (HBs, OVA, CSP, VZV glycoprotein E, all clinical-grade) and the
Adjuvant System AS01 were produced at GSK. Unless otherwise stated in
the ﬁgure legends, AS01 contained 100 μg/ml 3D-MPL (GSK), 100 µg/ml
QS-21 (Quillaja saponaria Molina, fraction 21, licensed by GSK from
Antigenics LLC, a wholly owned subsidiary of Agenus Inc., a Delaware, USA
corporation) and was formulated in liposomes. In experiments with RTS,S/
AS01, a variant of AS01 (AS01E = 50 μg/ml 3D-MPL (GSK), 50 µg/ml QS-21)
was used. Set-up experiments showed no impact of lower doses of AS01
on its adjuvanticity in mice (data not shown).
Human studies
All blood samples were obtained from the RTS,S vaccine clinical trial
(ClinicalTrials.gov NCT00075049).12 The clinical trial was conducted in
accordance with all applicable regulatory requirements, including the
Declaration of Helsinki (1996). The clinical trial was approved by
institutional review boards from the Walter Reed Army Institute of
Research (WRAIR) Human Use Review Committee (HURC) and the United
States Army Medical Research and Materiel Command (USAMRMC) Human
Subjects Research Review Board (HSRRB). Written-informed consent was
obtained from each participant prior to the performance of any study-
speciﬁc procedures in accordance with relevant ICH Guidelines, US Army
Regulations and principles of the Declaration of Helsinki. Serum IFNγ levels
at D0 and D1 after immunization were measured by ELISA (R&D Systems)
in 33/35 trial participants receiving RTS,S/AS01 due to missing data in 2
individuals.
Animal immunizations
Animal husbandry and experiments were ethically reviewed and carried
out in accordance with European Directive 2010/63/EU and the
GlaxoSmithKline Biologicals S.A. Policy on the Care, Welfare and Treatment
of Animals. For the malaria challenge model (conducted at WRAIR)
experiments were conducted under an approved animal use protocol in an
AAALACi accredited facility in compliance with the Animal Welfare Act and
other federal statutes and regulations relating to animals and experiments
involving animals and adheres to principles stated in the Guide for the
Care and Use of Laboratory Animals, NRC Publication, 2011 edition.
C57Bl/6 mice were purchased from Harlan Horst, Netherlands. Ifngr−/−,
Il18−/− and ROSA-stopﬂox−DTA mice were purchased from Jackson
Laboratories (USA). Nkp46(iCre) mice were a gift of Prof. Eric Vivier. Mice
were allocated across experimental groups by random draw. Experimen-
ters were not blinded during tests. The i.m. injections were performed in
6–8 week-old mice, in both hind limbs, in the gastrocnemius (gcm) muscles
and in a volume of 50 µl/muscle, unless otherwise stated. Iliac lymph nodes
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were identiﬁed as draining in set-up experiments, which also showed
minimal immune activation in non-draining lymph nodes. Anti-IL-12p40
mAb (C17.8, 0.5 mg i.p.) was purchased from BioXCell and injected i.p. the
day before immunization. Anti-IFNγ mAb (XMG1.2) (BioXCell), was injected
i.p. 48 h before immunization. Clodronate liposome and control liposomes
(Clodrosome) were injected i.m. (2 × 20 μl) in the gcm muscles 6 days
before immunization. For NHP studies, 4–6 years old Chinese rhesus
macaques were used. Animals had been previously used in unrelated
vaccination studies, but a resting period of 6 months minimum was
imposed to minimize any impact on this study. NHPs were randomized
and immunized intramuscularly in both left and right biceps with AS01
(250 μl/injection) and VZV glycoprotein E or HIV recombinant protein F4.
Axillary lymph nodes were used as dLNs and cervical lymph nodes as non-
draining lymph nodes.
Malaria challenge model
Mice were challenged i.v. on Day 0 with 3000 transgenic P. berghei
sporozoites expressing P. falciparum CSP, collected from a single mosquito
lot.29 Mice were monitored from Day 2–12 for parasitemia by blood smear
under microscope. Mice were considered infected and euthanized after
exhibiting parasitemia on two consecutive days. All mice were euthanized
on Day 12.
Microarray analysis
Total RNA was isolated by homogenizing pooled dLN in Tripure reagent (1
ml/100mg tissue; Roche Applied Science) and then extracted with
chloroform followed by RNeasy Minikit (Qiagen) according to the
manufacturer’s protocol. A DNAse treatment was applied on the RNeasy
column to avoid genomic DNA contamination. RNA was concentrated by
ethanol precipitation, and quantiﬁed by RiboGreen (Life Technologies). 1
µg of each RNA sample was used for target preparation, using a one-cycle
cDNA synthesis kit, and hybridized to GeneChip Whole Mouse Genome
430 2.0 arrays (Affymetrix). Data acquisition was performed using
GeneChip Operating Software (Affymetrix). Data were quality controlled
and normalized (RMA normalization) in R using Bioconductor packages.
The data analysis pipeline is presented in Supplementary Fig. 6. Linear
modeling and contrast analysis were performed using the limma R
package, PCA plots were generated using pca3d. Enrichment analysis on
PCA components were generated using the tmod and tagcloud packages.
Heatmaps were generated using the pheatmap packages. For identiﬁca-
tion of interplay between AS01 components, for each gene, an effect score
over PBS was calculated. The type of interplay for each DEG was identiﬁed
in R using the algorithm described in ref.15 Brieﬂy, an empirical Bayes
procedure (in limma R package) was used to estimate the contrasts that
make up the different forms of interplay and to assess their signiﬁcance.
The signiﬁcance of a particular form of interplay was subsequently
obtained by applying an intersection-union hypothesis testing procedure
to the proper combination of contrasts. Equivalence intervals of [−1,1] and
a p-value of <0.05 were used as cutoff. Process Network enrichment
analysis was performed in MetaCore (Thomson Reuters).
Code availability
R code with an implementation of the procedure to identify different forms
of interplay between AS01 components is included in the Supporting
Information of ref.15
Determination of antigen-speciﬁc T-cell and antibody responses to
vaccination
Antigen-speciﬁc antibody concentrations in the serum (deﬁned by internal
standards) were measured by ELISA, as previously described.7, 13 To assess
antigen-speciﬁc T-cell response, 106 splenocytes from immunized mice
were stimulated in vitro with peptide pools of 15-mers with 11 amino acids
overlap (1 µg/ml). Anti-CD49d and anti-CD28 antibodies (1 µg/ml, BD
Biosciences) were added to the culture and the cells were incubated 2 h at
37 °C 5% CO2 in RPMI 10% FCS + additives (l-Glutamine (2mM), Pennicilin/
Streptomycin (100 U/100 µg), sodium pyruvate 1mM and MEM non-
essential amino acids (1 × ) (all from Invitrogen)). Brefeldin A (BFA) (1 μg/
ml, BD Biosciences) was then added and cells were further cultured
overnight at 37 °C 5% CO2. Cell staining was performed as described
previously.7, 13 Brieﬂy, cells were washed and stained for surface markers,
then ﬁxed and permeabilized using the BD Cytoﬁx/Cytoperm solution kit.
Cells were then stained with αIL-2 FITC, anti-IFNγ-APC, and anti-TNF-α-PE
(all from BD) for 2 h at 4 °C. The samples were analyzed with the LSRII ﬂow
cytometer (BD) and FlowJo software. A complete list of antibodies used in
this study is presented in Supplementary Table 1.
Innate cell phenotyping
dLNs were ﬁrst treated by mechanical dissociation in 3 ml RPMI medium
containing DNase I (100 µg/ml, Roche), 1 % FCS and Liberase (Roche) at
0.26 U/ml for 30min under agitation at room temperature. Digestion was
stopped by adding 10mM EDTA and incubating on ice. Cells were ﬁltered
(100 µM nylon cell strainer, BD Biosciences), washed and resuspended in
PBS + 2mM EDTA + 2 % FCS. The analysis of innate cell phenotype was
performed as previously described.7 Monocytes were deﬁned as Ly6Chigh
CD11b+,Ly6G− cells and neutrophils were deﬁned as SSChigh, CD11b+,
Ly6Ghigh. After exclusion of neutrophil, monocyte, and lymphocyte
populations, DCs were gated as CD11cmidMHCIIhigh. For identiﬁcation of
IFNγ producing cells in mice, dLNs were dissociated and ﬁltered cells were
incubated for 3 h in RPMI 10% FCS + additives in the presence of BFA (1
µg/ml, BD Biosciences) and Monensin (1 µg/ml, BD Biosciences) at 37 °C 5%
C02. After treatment with 2.4G2 antibody for 10min to block the Fc
receptor, cells were stained for the following markers: NK1.1, TCRβ, TCRγδ,
CD45, CD8, CD49b, CD44, CD27, CD69, CD25, CD4, RORγ, EOMES, CXCR3, IL-
18R, and CD122 using antibodies from BD Bioscience or eBiosciences. For
NHP studies, collagenase-treated dLN cell suspensions were incubated for
5 h in RPMI 10% FCS + additives in the presence of BFA (1 µg/ml, BD
Biosciences) and Monensin (1 µg/ml, BD Biosciences) at 37 °C 5% C02. Cells
were then stained for the following surface markers: CD20, CD177, NKp46,
CD45, CD11c, CD123, CD8, CD11b, CD3, CD19, CD16, CD14, HLADR, CD4,
and TCRγδ. Cells were then ﬁxed and permeabilized using the BD Cytoﬁx/
Cytoperm solution kit and stained with anti-IFNγ APC, FITC or PeCy7.
Analysis of cytokine levels
For the assessment of pro-inﬂammatory cytokine concentration, dLNs were
collected after immunization at the indicated time points and stored at
−80 °C until further analysis. Organs were homogenized and cytokines
were measured in supernatants as described previously.7 Protein levels
were measured by Cytokine Bead Analysis (BD Biosciences) or ELISA (R&D
system) (mouse studies) or multiplex assay (Luminex,Milliplex Kit, Millipore)
(NHP studies). For qPCR analysis, RNA was isolated by homogenizing dLN
in Tripure reagent (Roche Applied Science) and then extracted with
chloroform followed by RNeasy Minikit (Qiagen) according to the
manufacturer’s protocol, with DNAse treatment. RNA was concentrated
by ethanol precipitation, and quantiﬁed by RiboGreen (Invitrogen). 500 ng
of total RNA were reverse-transcribed using Superscript II RNase H
(Invitrogen) as per manufacturer’s protocol. RNA expression was quantiﬁed
by real time PCR (RT-PCR) using the ABI SYBR Green Mastermix (Applied
Biosystems) (primers sequence for IFNγ [5′-GCATTCATGAGTATTGC-
CAAGTTTG-3′, 5′-CGGATGAGCTCATTGAATGCTT-3′], for HPRT [5′-
GCAAACTTTGCTTTCCCTGG-3′, 5′-ACTTCGAGAGGTCCTTTTCACC-3], primer
efﬁciency 90–110%). RT-PCR was run the ABI Prism 7900HT Sequence
Detection System (Perkin Elmer). Expression levels were quantiﬁed using
the comparative Ct method and gene expression was determined relative
to the mean value of the matched PBS-treated controls.
Statistical analyzes
Sample size with adequate statistical power in animal studies was
determined based on previous experiments. Where appropriate, data
were log-tranformed and assumed to have a normal distribution.
Depending on the study design, a Student's t-test or an ANOVA (one- or
two-way, depending on the experimental design) followed by Bonferroni
corrected t-test were applied to identify differences between treatments.
Only signiﬁcant differences are reported on the graphs. Two-way ANOVA
was performed to assess experiments with a 2 × 2 factorial design (for
instance, when mice from 2 different strains were vaccinated with either
AS01 or PBS + Ag). When 2- way ANOVA is performed, the interaction test
addresses the question whether the effect of treatment (for instance
vaccination) is the same in both conditions tested (for instance 2 different
mouse strains). If the p-value is < 0.05, then the treatment has different
effects in the two conditions. Statistical signiﬁcance: *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001.
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Data availability
Transcriptomics data are available on GEO database with access number
GSE98322. Preclinical data that support the ﬁndings of this study are
available from GSK Vaccines but restrictions apply to the availability of
these data. Data are, however, available from the authors upon reasonable
request and with permission of GSK Vaccines. The results summary for the
clinical study (GSK study number 257049/027 - NCT00075049) is available
on the GSK Clinical Study Register and can be accessed at www.gsk-
clinicalstudyregister.com. For interventional studies that evaluate our
medicines, anonymized patient-level data will be made available to
independent researchers, subject to review by an independent panel, at
www.clinicalstudydatarequest.com within 6 months of publication. To
protect the privacy of patients and individuals involved in our studies, GSK
does not publically disclose patient-level data.
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